The chief medical officer of Cellularity discussed the big picture implications of a new analysis of patient samples from legacy studies evaluating MLASC therapy in Crohn disease.
Adrian Kilcoyne, MD, MPH, MBA
Advertisement
Articles by Adrian Kilcoyne, MD, MPH, MBA
The chief medical officer of Celularity discussed MLASC and a new analysis of gene and protein signatures from patients treated in legacy clinical trials that he presented at ASGCT’s 2023 conference.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CGTlive®
1
PreBLA Meeting With FDA Sinks uniQure’s Hopes for Approval of Huntington Disease Gene Therapy AMT-130 Based Primarily on Phase 1/2 Data
2
FDA Activity Recap: October 2025 Features New Platform Technology Designation, RDEA Pilot Program Selection, and More
3
